Related Experiment Video
Updated: Mar 11, 2026
11:31
Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate
Published on: September 18, 2013
10.5K
Screening for chemical modulators for LRRK2
1SITraN, Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, U.K.
Biochemical Society Transactions
|December 4, 2016
Summary
Researchers are exploring new ways to find drugs that affect leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease (PD). This involves discussing methods for screening compounds that modulate LRRK2 activity and cellular functions.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Leucine-rich repeat kinase 2 (LRRK2) is a key genetic factor in Parkinson's disease (PD).
- Mutations in LRRK2 are linked to both familial and sporadic forms of PD.
- Understanding LRRK2's role necessitates the development of chemical modulators.
Purpose of the Study:
- To review strategies for identifying chemical compounds that modulate LRRK2 function.
- To discuss the importance of rigorous preparation for high-throughput screening.
- To explore both enzymatic and phenotypic screening approaches for LRRK2 modulators.
Main Methods:
- Focus on enzymatic screens targeting LRRK2's catalytic activity.
- Highlight the utility of phenotypic screens for assessing cellular effects.
- Emphasize the need for robust assay development for accurate compound assessment.
Main Results:
- The study discusses the pipeline for initiating drug screens.
- It outlines various LRRK2 inhibitor screens and phenotypic screens.
- The preparation for accurate, high-throughput assessment is crucial.
Conclusions:
- Developing effective modulators of LRRK2 is critical for Parkinson's disease research.
- Both enzymatic and phenotypic screening methods offer valuable approaches.
- Rigorous methodology is essential for successful drug discovery targeting LRRK2.
